Baillie Gifford & Co. Boosts Stake in Guardant Health, Inc. $GH

Baillie Gifford & Co. increased its holdings in shares of Guardant Health, Inc. (NASDAQ:GH) by 6.6% during the third quarter, HoldingsChannel.com reports. The fund owned 5,127,692 shares of the company’s stock after buying an additional 317,906 shares during the period. Baillie Gifford & Co.’s holdings in Guardant Health were worth $320,378,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Signaturefd LLC lifted its stake in Guardant Health by 50.5% in the 2nd quarter. Signaturefd LLC now owns 635 shares of the company’s stock worth $33,000 after purchasing an additional 213 shares in the last quarter. IFP Advisors Inc increased its holdings in shares of Guardant Health by 120.1% in the second quarter. IFP Advisors Inc now owns 612 shares of the company’s stock valued at $33,000 after purchasing an additional 334 shares during the last quarter. Main Management ETF Advisors LLC lifted its position in Guardant Health by 1.7% during the second quarter. Main Management ETF Advisors LLC now owns 21,257 shares of the company’s stock worth $1,106,000 after buying an additional 348 shares in the last quarter. CWM LLC boosted its stake in Guardant Health by 21.6% during the third quarter. CWM LLC now owns 2,020 shares of the company’s stock worth $126,000 after buying an additional 359 shares during the last quarter. Finally, F m Investments LLC boosted its stake in Guardant Health by 1.2% during the second quarter. F m Investments LLC now owns 39,099 shares of the company’s stock worth $2,035,000 after buying an additional 471 shares during the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Guardant Health Stock Performance

Guardant Health stock opened at $114.75 on Friday. The company’s 50 day simple moving average is $105.24 and its 200-day simple moving average is $77.45. Guardant Health, Inc. has a 1 year low of $34.88 and a 1 year high of $120.74. The company has a market capitalization of $14.46 billion, a price-to-earnings ratio of -35.75 and a beta of 1.58.

Guardant Health (NASDAQ:GH) last posted its earnings results on Wednesday, October 29th. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.09. During the same quarter last year, the company posted ($0.88) earnings per share. The company’s revenue for the quarter was up 38.5% on a year-over-year basis. Equities analysts expect that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have issued reports on GH shares. JPMorgan Chase & Co. raised their target price on Guardant Health from $90.00 to $120.00 and gave the stock an “overweight” rating in a research note on Monday, December 15th. Stifel Nicolaus upped their price objective on shares of Guardant Health from $100.00 to $120.00 and gave the company a “buy” rating in a report on Friday, January 9th. Evercore ISI set a $105.00 target price on shares of Guardant Health and gave the stock an “in-line” rating in a research note on Monday, January 5th. Wells Fargo & Company boosted their target price on shares of Guardant Health from $93.00 to $120.00 and gave the company an “overweight” rating in a report on Monday, December 15th. Finally, Canaccord Genuity Group increased their price target on shares of Guardant Health from $100.00 to $125.00 and gave the company a “buy” rating in a research note on Monday, December 22nd. Twenty-one investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Guardant Health presently has an average rating of “Moderate Buy” and an average price target of $102.81.

Insider Buying and Selling at Guardant Health

In other news, insider Terilyn J. Monroe sold 8,571 shares of the firm’s stock in a transaction that occurred on Wednesday, January 21st. The shares were sold at an average price of $114.09, for a total value of $977,865.39. Following the completion of the transaction, the insider owned 20,990 shares of the company’s stock, valued at approximately $2,394,749.10. This trade represents a 28.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Medina Manuel Hidalgo sold 1,250 shares of Guardant Health stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $105.00, for a total transaction of $131,250.00. Following the completion of the transaction, the director owned 797 shares of the company’s stock, valued at $83,685. This trade represents a 61.06% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 445,123 shares of company stock valued at $46,600,702. Corporate insiders own 6.10% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.